Supplementary Table 2.
Performance of different staging systems in training cohort and validation cohorts by univariate analysis
| Univariate analysis | C-index (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cohort 1 (n = 4166) | Cohort 2 (n = 1978) | Cohort 3 (n = 808) | Cohort 4 (n = 244) | |||||
| OS | RFS | OS | RFS | OS | RFS | OS | RFS | |
| Shanghai score | 0.74 (0.73–0.75) | 0.68 (0.67–0.69) | 0.72 (0.70–0.74) | 0.66 (0.64–0.68) | 0.70 (0.66–0.74) | 0.63 (0.60–0.66) | 0.70 (0.65–0.76) | 0.68 (0.63–0.72) |
| BCLC | 0.66 (0.65–0.68) | 0.62 (0.60–0.63) | 0.65 (0.63–0.67) | 0.61 (0.59–0.63) | 0.57 (0.53–0.61) | 0.56 (0.53–0.59) | 0.61 (0.56–0.66) | 0.60 (0.56–0.64) |
| AJCC-TNM | 0.66 (0.65–0.67) | 0.61 (0.60–0.62) | 0.66 (0.64–0.68) | 0.62 (0.60–0.63) | 0.60 (0.56–0.64) | 0.57 (0.55–0.60) | 0.60 (0.54–0.65) | 0.58 (0.54–0.62) |
| CLIP | 0.64 (0.62–0.65) | 0.60 (0.58–0.61) | 0.62 (0.60–0.64) | 0.58 (0.57–0.60) | 0.59 (0.55–0.63) | 0.56 (0.53–0.59) | 0.63 (0.57–0.70) | 0.65 (0.61–0.70) |
| Okuda | 0.57 (0.56–0.58) | 0.55 (0.54–0.55) | 0.56 (0.54–0.57) | 0.54 (0.53–0.55) | 0.53 (0.50–0.55) | 0.52 (0.51–0.54) | 0.59 (0.54–0.64) | 0.57 (0.53–0.61) |
| CS stage | 0.66 (0.65–0.68) | 0.61 (0.60–0.62) | 0.66 (0.64–0.68) | 0.62 (0.60–0.63) | 0.55 (0.52–0.58) | 0.55 (0.53–0.57) | 0.61 (0.55–0.66) | 0.60 (0.56–0.63) |
| UNOS-TNM | 0.66 (0.65–0.67) | 0.62 (0.60–0.63) | 0.67 (0.65–0.69) | 0.62 (0.61–0.64) | 0.57 (0.53–0.60) | 0.56 (0.53–0.58) | 0.64 (0.59–0.69) | 0.64 (0.59–0.68) |
| JIS score | 0.65 (0.64–0.66) | 0.60 (0.59–0.61) | 0.66 (0.64–0.67) | 0.61 (0.60–0.63) | 0.54 (0.52–0.57) | 0.52 (0.50–0.54) | 0.62 (0.57–0.67) | 0.61 (0.57–0.65) |
| Japan-TNM | 0.64 (0.63–0.65) | 0.60 (0.59–0.61) | 0.65 (0.63–0.67) | 0.61 (0.59–0.62) | 0.54 (0.51–0.57) | 0.53 (0.51–0.55) | 0.62 (0.56–0.67) | 0.61 (0.57–0.65) |
| CUPI | 0.64 (0.63–0.65) | 0.59 (0.58–0.60) | 0.51 (0.50–0.51) | 0.50 (0.50–0.51) | 0.58 (0.54–0.63) | 0.57 (0.54–0.59) | 0.61 (0.55–0.67) | 0.61 (0.57–0.66) |
| Eastern stage | 0.66 (0.65–0.68) | 0.61 (0.60–0.63) | 0.63 (0.61–0.65) | 0.60 (0.59–0.62) | 0.58 (0.53–0.63) | 0.56 (0.53–0.59) | 0.64 (0.59–0.69) | 0.61 (0.57–0.65) |
| HKLC | 0.65 (0.64–0.66) | 0.61 (0.60–0.62) | 0.65 (0.63–0.67) | 0.61 (0.59–0.62) | 0.61 (0.57–0.65) | 0.58 (0.56–0.61) | 0.61 (0.56–0.67) | 0.60 (0.55–0.64) |
OS: Overall survival; RFS: Recurrence-free survival; BCLC: Barcelona Clinic Liver Cancer staging; AJCC: American Joint Committee on Cancer; TNM: Tumor node metastasis; CLIP: Cancer of the Liver Italian Program score; CS: Chinese Staging; UNOS: United Network for Organ Sharing; JIS: Japan Integrated Staging score; CUPI: Chinese University Prognostic Index staging; HKLC: Hong Kong Liver Cancer Staging System; C-index: Concordance index; CI: Confidence interval.